BACKGROUND: Patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) have access to a growing number of probiotic products marketed to improve digestive health. It is unclear how patients make decisions about probiotics and what role they expect their gastroenterologists to play as they consider using probiotics. Understanding patients' knowledge, attitudes and expectations of probiotics may help gastroenterologists engage patients in collaborative discussions about probiotics. STUDY: Focus groups were conducted with patients with IBD and IBS at the Cleveland Clinic, Mayo Clinic, and Johns Hopkins University. Inductive analytic methods were used to identify common themes and draw interpretations from focus group narratives. RESULTS: One hundred thirty-six patients participated in 22 focus groups between March and August 2009. Patients viewed probiotics as an appealing alternative to pharmaceutical drugs and understood probiotics as a more "natural," low-risk therapeutic option. Many patients were hesitant to use them without consulting their gastroenterologists. Patients would weigh the risks and benefits of probiotics, their disease severity and satisfaction with current treatments when considering probiotic use. CONCLUSIONS: Patients are interested in probiotics but have many unanswered questions about their use. Our findings suggest that patients with IBD and IBS will look to gastroenterologists and other clinicians as trustworthy advisors regarding the utility of probiotics as an alternative or supplement to pharmaceutical drugs. Gastroenterologists and other clinicians who care for patients with these diseases should be prepared to discuss the potential benefits and risks of probiotics and assist patients in making informed decisions about their use.
BACKGROUND:Patients with inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) have access to a growing number of probiotic products marketed to improve digestive health. It is unclear how patients make decisions about probiotics and what role they expect their gastroenterologists to play as they consider using probiotics. Understanding patients' knowledge, attitudes and expectations of probiotics may help gastroenterologists engage patients in collaborative discussions about probiotics. STUDY: Focus groups were conducted with patients with IBD and IBS at the Cleveland Clinic, Mayo Clinic, and Johns Hopkins University. Inductive analytic methods were used to identify common themes and draw interpretations from focus group narratives. RESULTS: One hundred thirty-six patients participated in 22 focus groups between March and August 2009. Patients viewed probiotics as an appealing alternative to pharmaceutical drugs and understood probiotics as a more "natural," low-risk therapeutic option. Many patients were hesitant to use them without consulting their gastroenterologists. Patients would weigh the risks and benefits of probiotics, their disease severity and satisfaction with current treatments when considering probiotic use. CONCLUSIONS:Patients are interested in probiotics but have many unanswered questions about their use. Our findings suggest that patients with IBD and IBS will look to gastroenterologists and other clinicians as trustworthy advisors regarding the utility of probiotics as an alternative or supplement to pharmaceutical drugs. Gastroenterologists and other clinicians who care for patients with these diseases should be prepared to discuss the potential benefits and risks of probiotics and assist patients in making informed decisions about their use.
Authors: Krista L Harrison; Gail Geller; Patricia Marshall; Jon Tilburt; Marybeth Mercer; Margaret A Brinich; Janelle Highland; Ruth M Farrell; Richard R Sharp Journal: AJOB Prim Res Date: 2012-06-19
Authors: Krista L Harrison; Ruth M Farrell; Margaret A Brinich; Janelle Highland; MaryBeth Mercer; Jennifer B McCormick; Jon Tilburt; Gail Geller; Patricia Marshall; Richard R Sharp Journal: Health Expect Date: 2012-12-28 Impact factor: 3.377
Authors: Geoffrey C Wall; Ginelle A Bryant; Michelle M Bottenberg; Erik D Maki; Andrew R Miesner Journal: World J Gastroenterol Date: 2014-07-21 Impact factor: 5.742
Authors: Jennifer B McCormick; Rachel R Hammer; Ruth M Farrell; Gail Geller; Katherine M James; Edward V Loftus; Mary Beth Mercer; Jon C Tilburt; Richard R Sharp Journal: Health Qual Life Outcomes Date: 2012-03-08 Impact factor: 3.186
Authors: Sarah L Bridgman; Meghan B Azad; Catherine J Field; Nicole Letourneau; David W Johnston; Bonnie J Kaplan; Anita L Kozyrskyj Journal: BMC Complement Altern Med Date: 2014-09-29 Impact factor: 3.659
Authors: Melody J Slashinski; Sheryl A McCurdy; Laura S Achenbaum; Simon N Whitney; Amy L McGuire Journal: BMC Med Ethics Date: 2012-10-30 Impact factor: 2.652
Authors: A P S Hungin; C Mulligan; B Pot; P Whorwell; L Agréus; P Fracasso; C Lionis; J Mendive; J-M Philippart de Foy; G Rubin; C Winchester; N de Wit Journal: Aliment Pharmacol Ther Date: 2013-08-27 Impact factor: 8.171